• Bloomberg


Ajinomoto Co. will pay as much as ¥10 billion to buy the Japanese rights to develop and sell a drug for treating ulcerative colitis.

A contract with German drugmaker Dr. Falk Pharma GmbH is scheduled to be signed this month, Ajinomoto spokeswoman Michiko Wada said. Regulatory approval to sell Salofalk, a treatment for ulcerative colitis, may be gained as early as 2011.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.